Skip to main content

alpha7nACHR_Nacho_GCAMP7s
(Plasmid #182940)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 182940 Standard format: Plasmid sent in bacteria as agar stab 1 $94
DNA 182940-D50 50 μg of DNA in Tris buffer $495
DNA 182940-D100 100 μg of DNA in Tris buffer $585

Backbone

  • Vector backbone
    synthesized
  • Backbone manufacturer
    Vectorbuilder
  • Total vector size (bp) 8636
  • Modifications to backbone
    EF1 alpha promoter driving NACH7_IRES_Nacho, CMV promoter driving GCAMP7s-CAAX
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    NACH7
  • Alt name
    alpha7 nicotinic acetylcholine receptor
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1509
  • Entrez Gene
    CHRNA7 (a.k.a. CHRNA7-2, NACHRA7, nAChR7)
  • Promoter EF1alpha

Cloning Information

  • Cloning method Gibson Cloning
  • 5′ sequencing primer TCAAGCCTCAGACAGTGGTTC
  • 3′ sequencing primer CCTCACATTGCCAAAAGACG
  • (Common Sequencing Primers)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    synthesized based on Genbank Sequence

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry

Trademarks:

  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Human NACH7 expression plasmid coexpressing mouse NACHO chaperone protein for mammalian expression of alpha7 nicotinic acetylcholine receptors in mammalian cells. The plasmid contains the membrane targeted (CAAX sequence) GCAMP7s calcium reporter to detect NACH7 mediated calcium influx.

Purpose

Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.

Delivery

  • Amount 50 μg
  • Concentration 1 μg/μL
  • Pricing $495 USD
  • Storage 4 ℃ (short-term) or -20 ℃ (long-term)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry

Quality Control

Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.

Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.

Purpose

Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.

Delivery

  • Amount 100 μg
  • Concentration 1 μg/μL
  • Pricing $585 USD
  • Storage 4 ℃ (short-term) or -20 ℃ (long-term)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry

Quality Control

Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.

Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    alpha7nACHR_Nacho_GCAMP7s was a gift from Robert Brenner (Addgene plasmid # 182940 ; http://n2t.net/addgene:182940 ; RRID:Addgene_182940)
  • For your References section:

    Dequalinium chloride is an antagonists of alpha7 nicotinic acetylcholine receptors. Belanger-Coast MG, Zhang M, Bugay V, Gutierrez RA, Gregory SR, Yu W, Brenner R. Eur J Pharmacol. 2022 Jun 15;925:175000. doi: 10.1016/j.ejphar.2022.175000. Epub 2022 May 4. 10.1016/j.ejphar.2022.175000 PubMed 35525312